Incyte (INCY) Liabilities and Shareholders Equity (2010 - 2026)
Incyte posted quarterly Liabilities and Shareholders Equity of $7.3 billion for Q1 2026, up 27.65% year-on-year from $5.7 billion in Q1 2025, and up 5.48% on a QoQ basis from $7.0 billion in Q4 2025.
Incyte (INCY) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $7.3 billion in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.65% year-over-year to $7.3 billion; the trailing twelve-month figure through Mar 2026 stood at $26.4 billion (up 26.74% YoY), and the FY2025 full-year result was $7.0 billion, up 27.8% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $7.3 billion, up from $7.0 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $7.3 billion in Q1 2026 and bottomed at $4.7 billion in Q2 2024.
- The 5-year median for Liabilities and Shareholders Equity is $5.8 billion (2025), against an average of $6.0 billion.
- The widest annual swing landed in 2022, when Liabilities and Shareholders Equity jumped 38.04%; it then retreated 24.91% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $5.8 billion in 2022, then climbed by 16.11% to $6.8 billion in 2023, then fell by 19.73% to $5.4 billion in 2024, then advanced by 27.8% to $7.0 billion in 2025, then gained by 5.48% to $7.3 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $7.3 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 7.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.34 Bn |
| Dec 31, 2025 | 6.96 Bn |
| Sep 30, 2025 | 6.33 Bn |
| Jun 30, 2025 | 5.82 Bn |
| Mar 31, 2025 | 5.75 Bn |
| Dec 31, 2024 | 5.44 Bn |
| Sep 30, 2024 | 5.01 Bn |
| Jun 30, 2024 | 4.66 Bn |
| Mar 31, 2024 | 7.14 Bn |
| Dec 31, 2023 | 6.78 Bn |
| Sep 30, 2023 | 6.39 Bn |
| Jun 30, 2023 | 6.21 Bn |
| Mar 31, 2023 | 5.80 Bn |
| Dec 31, 2022 | 5.84 Bn |
| Sep 30, 2022 | 5.51 Bn |
| Jun 30, 2022 | 5.32 Bn |
| Mar 31, 2022 | 5.05 Bn |
| Dec 31, 2021 | 4.93 Bn |
| Sep 30, 2021 | 4.20 Bn |
| Jun 30, 2021 | 3.90 Bn |
| Mar 31, 2021 | 3.66 Bn |
| Dec 31, 2020 | 3.56 Bn |
| Sep 30, 2020 | 3.31 Bn |
| Jun 30, 2020 | 3.21 Bn |
| Mar 31, 2020 | 2.75 Bn |
| Dec 31, 2019 | 3.43 Bn |
| Sep 30, 2019 | 174.80 Mn |
| Jun 30, 2019 | 2.95 Bn |
| Mar 31, 2019 | 2.75 Bn |
| Dec 31, 2018 | 2.65 Bn |
| Sep 30, 2018 | 2.52 Bn |
| Jun 30, 2018 | 2.40 Bn |
| Mar 31, 2018 | 2.31 Bn |
| Dec 31, 2017 | 2.30 Bn |
| Sep 30, 2017 | 2.37 Bn |
| Jun 30, 2017 | 1.64 Bn |
| Mar 31, 2017 | 1.61 Bn |
| Dec 31, 2016 | 1.64 Bn |
| Sep 30, 2016 | 1.54 Bn |
| Jun 30, 2016 | 1.42 Bn |
| Mar 31, 2016 | 1.10 Bn |
| Dec 31, 2015 | 1.01 Bn |
| Sep 30, 2015 | 931.93 Mn |
| Jun 30, 2015 | 930.34 Mn |
| Mar 31, 2015 | 862.62 Mn |
| Dec 31, 2014 | 796.48 Mn |
| Sep 30, 2014 | 785.27 Mn |
| Jun 30, 2014 | 679.11 Mn |
| Mar 31, 2014 | 666.83 Mn |
| Dec 31, 2013 | 629.57 Mn |
| Sep 30, 2013 | 357.40 Mn |
| Jun 30, 2013 | 334.22 Mn |
| Mar 31, 2013 | 330.28 Mn |
| Dec 31, 2012 | 330.42 Mn |
| Sep 30, 2012 | 296.54 Mn |
| Jun 30, 2012 | 311.97 Mn |
| Mar 31, 2012 | 293.59 Mn |
| Dec 31, 2011 | 328.96 Mn |
| Sep 30, 2011 | 371.22 Mn |
| Jun 30, 2011 | 416.66 Mn |
| Mar 31, 2011 | 459.61 Mn |
| Dec 31, 2010 | 489.58 Mn |